Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $6.0 million.

  • Voyager Therapeutics' Non-cash Items rose 3002.42% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 3002.42%. This contributed to the annual value of $4.8 million for FY2024, which is 5715.99% down from last year.
  • As of Q3 2025, Voyager Therapeutics' Non-cash Items stood at $6.0 million, which was up 3002.42% from $247000.0 recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Non-cash Items registered a high of $11.3 million during Q4 2023, and its lowest value of $247000.0 during Q2 2025.
  • For the 5-year period, Voyager Therapeutics' Non-cash Items averaged around $4.7 million, with its median value being $3.8 million (2021).
  • As far as peak fluctuations go, Voyager Therapeutics' Non-cash Items soared by 31147.91% in 2023, and later crashed by 9739.48% in 2025.
  • Voyager Therapeutics' Non-cash Items (Quarter) stood at $3.6 million in 2021, then decreased by 24.01% to $2.7 million in 2022, then soared by 311.48% to $11.3 million in 2023, then plummeted by 57.16% to $4.8 million in 2024, then increased by 23.75% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $247000.0 for Q2 2025, and $499000.0 during Q1 2025.